An amyloid PET scan is a brain-imaging test that uses an injected tracer to estimate amyloid plaque buildup in adults with thinking problems. It detects plaques well, but it cannot alone diagnose Alzheimer's, often costs $3,000 or more, and guides next care steps. Doctors use it alongside memory testing, exams, and other workups. The result helps sort likely causes and shape what to do next.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the scan measures
- How accurate is it, and where does it stop?
- Who should consider it?
- What does it cost, and does Medicare cover it?
- What are practical next steps?
- Frequently Asked Questions
What the scan measures
According to Nebraska Medicine's explainer, amyloid PET uses an injected fluorine-18 tracer that binds beta-amyloid plaques. The scan estimates neuritic plaque density in adults with cognitive impairment evaluated for Alzheimer's disease and other causes of decline.
A negative scan showing no or sparse plaques argues against Alzheimer's as the cause. According to the same Nebraska Medicine source, that pattern is inconsistent with an Alzheimer's neuropathological diagnosis at imaging time and lowers the likelihood that impairment is due to Alzheimer's disease.
How accurate is it, and where does it stop?
The test accurately detects beta-amyloid plaques when they are present. Plaques themselves can occur with more than one disease process, so a positive scan does not name the exact clinical disease.
An NIH review in Alzheimer's and Dementia reaches the same limit: although amyloid PET accurately detects plaques, it does not distinguish among different diseases linked to that pathology and must remain adjunct to other evaluation, as described in the NIH review. Families should treat it as one strong clue, not a final answer.
Who should consider it?
Use is narrowest when Alzheimer's is suspected and the result would change care. Updated 2025 Alzheimer's Association-SNMMI criteria rate 7 scenarios as appropriate, 2 uncertain, and 8 rarely appropriate, according to Healio's guideline report.
The focus is mild cognitive impairment, often called MCI, or dementia where Alzheimer's is suspected and results would change management. People with clear alternative causes, very mild concerns unlikely to alter care, or no cognitive symptoms are generally poor candidates.
What does it cost, and does Medicare cover it?
Out-of-pocket amyloid PET typically averages $3,000 or more per test, according to NeurologyLive's coverage report. That price creates a barrier when coverage or supplemental insurance does not apply. Coverage rules changed on Oct.
13, 2023, when CMS retired national determination 220.6.20. That action ended coverage-with-evidence-development and the one-scan-per-lifetime limit and left amyloid-PET coverage to regional Medicare Administrative Contractors. Ask the ordering center for a written coverage check before scheduling.
What are practical next steps?
A newer blood pathway can precede PET for some symptomatic adults. In May 2025, FDA cleared Lumipulse G pTau217/beta-amyloid 1-42 plasma ratio for adults age 50 and older with cognitive symptoms in specialty care, not for routine screening of people without symptoms and not as a standalone diagnosis.
After a positive blood biomarker or an uncertain case, confirmatory amyloid PET or spinal-fluid testing is often the practical next move. That proof matters because anti-amyloid drugs such as lecanemab require documented brain amyloid with mild cognitive impairment or mild dementia.
- Bring medication lists, cognitive test results, and prior brain images
- Ask whether PET or spinal-fluid testing fits faster at your center
- Confirm treatment eligibility, risks, monitoring, and follow-up visits
- Discuss driving, work, finances, and caregiver support while results are pending
Frequently Asked Questions
Can a blood test replace amyloid PET?
No. The cleared plasma ratio helps assess symptomatic adults in specialty care, but positive or uncertain cases often still need PET or spinal-fluid confirmation.
Will one positive scan qualify someone for lecanemab?
No. Eligibility also requires mild cognitive impairment or mild dementia, plus safety screening and ongoing monitoring set by the treatment center.





